SEAGEN INC (SGEN)

US81181C1045 - Common Stock

228.74  -0.16 (-0.07%)

After market: 228.95 +0.21 (+0.09%)

Fundamental Rating

4

Taking everything into account, SGEN scores 4 out of 10 in our fundamental rating. SGEN was compared to 586 industry peers in the Biotechnology industry. SGEN has a great financial health rating, but its profitability evaluates not so good. SGEN is valued quite expensive, but it does show an excellent growth.



2

1. Profitability

1.1 Basic Checks

In the past year SGEN has reported negative net income.
SGEN had a negative operating cash flow in the past year.
SGEN had negative earnings in 4 of the past 5 years.
In the past 5 years SGEN reported 4 times negative operating cash flow.

1.2 Ratios

Looking at the Return On Assets, with a value of -20.64%, SGEN belongs to the top of the industry, outperforming 82.06% of the companies in the same industry.
With an excellent Return On Equity value of -29.41%, SGEN belongs to the best of the industry, outperforming 81.40% of the companies in the same industry.
Industry RankSector Rank
ROA -20.64%
ROE -29.41%
ROIC N/A
ROA(3y)-6.47%
ROA(5y)-8.28%
ROE(3y)-8.73%
ROE(5y)-10.42%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Gross Margin of SGEN (75.39%) is better than 84.88% of its industry peers.
SGEN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for SGEN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 75.39%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-5.99%
GM growth 5Y-2.28%

7

2. Health

2.1 Basic Checks

SGEN does not have a ROIC to compare to the WACC, probably because it is not profitable.
SGEN has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SGEN has more shares outstanding
There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

SGEN has an Altman-Z score of 23.31. This indicates that SGEN is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 23.31, SGEN belongs to the best of the industry, outperforming 94.68% of the companies in the same industry.
There is no outstanding debt for SGEN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 23.31
ROIC/WACCN/A
WACC10.94%

2.3 Liquidity

SGEN has a Current Ratio of 2.67. This indicates that SGEN is financially healthy and has no problem in meeting its short term obligations.
SGEN's Current ratio of 2.67 is on the low side compared to the rest of the industry. SGEN is outperformed by 73.26% of its industry peers.
A Quick Ratio of 2.12 indicates that SGEN has no problem at all paying its short term obligations.
SGEN has a Quick ratio of 2.12. This is in the lower half of the industry: SGEN underperforms 76.91% of its industry peers.
Industry RankSector Rank
Current Ratio 2.67
Quick Ratio 2.12

7

3. Growth

3.1 Past

The earnings per share for SGEN have decreased strongly by -16.23% in the last year.
Looking at the last year, SGEN shows a very strong growth in Revenue. The Revenue has grown by 23.40%.
Measured over the past years, SGEN shows a very strong growth in Revenue. The Revenue has been growing by 32.40% on average per year.
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.65%
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y32.4%
Sales Q2Q%27.12%

3.2 Future

The Earnings Per Share is expected to grow by 32.31% on average over the next years. This is a very strong growth
SGEN is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 26.49% yearly.
EPS Next Y-28.74%
EPS Next 2Y17.92%
EPS Next 3Y29.83%
EPS Next 5Y32.31%
Revenue Next Year28.4%
Revenue Next 2Y30.41%
Revenue Next 3Y29.91%
Revenue Next 5Y26.49%

3.3 Evolution

The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.

1

4. Valuation

4.1 Price/Earnings Ratio

SGEN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SGEN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

SGEN's earnings are expected to grow with 29.83% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.92%
EPS Next 3Y29.83%

0

5. Dividend

5.1 Amount

No dividends for SGEN!.
Industry RankSector Rank
Dividend Yield N/A

SEAGEN INC

NASDAQ:SGEN (12/13/2023, 7:12:24 PM)

After market: 228.95 +0.21 (+0.09%)

228.74

-0.16 (-0.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap43.15B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -20.64%
ROE -29.41%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 75.39%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.63
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 2.67
Quick Ratio 2.12
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-16.23%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-28.74%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)23.4%
Revenue growth 3Y28.88%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y